Diabetic cardiomyopathy is characterized by reduced cardiac contractility independent of vascular disease. A contributor to contractile dysfunction in the diabetic heart is impaired sarcoplasmic reticulum function with reduced sarco(endo)plasmic reticulum Ca 2+ -ATPase (SERCA2a) pump activity, leading to disturbed intracellular calcium handling. It is currently unclear if increasing SERCA2a activity in hearts with existing diabetic cardiomyopathy could still improve calcium flux and contractile performance.
Introduction
Congestive heart failure is an important medical problem resulting in significant morbidity and mortality. Heart failure occurs at an increased incidence in patients with diabetes mellitus. In addition to an increased propensity for coronary vascular disease, resulting in ischemic heart disease, diabetic cardiomyopathy occurs in combination with or independent of coronary vascular disease (12) . In the diabetic heart, abnormal Ca 2+ handling during the contractile cycle results in a decreased upstroke phase of the Ca 2+ transient due to diminished release of Ca 2+ from the sarcoplasmic reticulum (SR) by ryanodine receptor (RyR)2 (2, 17) . In addition, the diastolic decline of the Ca 2+ transient
is diminished due to reduced activity of the sarco(endo)plasmic reticulum Ca 2+ -ATPase (SERCA2a) pump (5) .
Most functional studies indicate decreased SERCA2a activity and protein level in diabetic cardiomyopathy (10, 18) . Efforts have focused on increasing expression of SERCA2a in order to alleviate contractile dysfunction in animal models of diabetic cardiomyopathy. Previous studies have shown that constitutive SERCA2a overexpression, with elevated SERCA2a levels before the introduction of diabetes-induced cardiomyopathy, prevented contractile abnormalities and calcium handling abnormalities in transgenic mice (18) and rats (20) . These studies show that "prophylactic" SERCA2a over-expression in a transgenic model is able to preserve cardiac function and myocyte contractile performance in diabetic animals. It remains unclear however, if an established diabetic cardiomyopathy with diminished contractile function and abnormal Ca 2+ handling can be reverted towards normal by inducible expression of SERCA2a in cardiac myocytes. It has been reported that adenoviral gene transfer of SERCA2a to the whole heart in vivo improved left ventricular mechanical and energetic functions in a type II diabetes model of cardiomyopathy in rats (14) , however, no data is available regarding Ca 2+ handling or contractility at the cardiac myocyte level.
The lack of information at the cellular level using an adenoviral gene transfer approach may be due to technical difficulties to assess calcium handling and cell shortening in transfected cardiac myocytes since adenoviral transfer is inhomogeneous. In addition, adenoviral administration can lead to inflammatory process that can jeopardize the specific effect of up-regulated SERCA2a. In this work we tested the hypothesis that conditional increased SERCA2a expression can return cardiac function, Ca 2+ handling and contractility at the cardiac myocyte level towards normal in animals with already established diabetes-induced cardiomyopathy. For this purpose we utilized a double transgenic mouse model in which a tetracycline system leads to inducible, cardiacmyocyte specific SERCA2a expression (tet-on SERCA2a) (16) . We demonstrate that, in vivo, inducible SERCA2a expression is able to correct calcium-handling abnormalities and restores contractility of cardiac myocytes of diabetic mice towards normal and results in consequently improved global cardiac function without detrimental effects.
Materials and Methods
Generation of Transgenic Mice. Transgenic mice expressing a codon-optimized reverse tetracycline transactivator driven by the cardiac specific alpha-myosin heavy chain promoter (MHC-rtTA) have been previously described (16, 19) . The inducible SERCA2a transgene construct was created by cloning the tetracycline response element (Tet-RE) in front of a rat SERCA2a transgene described previously (7), containing the first and second introns and a C-terminal FLAG tag. was assessed with an antibody targeted to the N-terminus (Santa Cruz Biotechnology).
Other antibodies used were anti-phospholamban (Affinity Bioreagents, Golden, CO),
anti-phospho-phospholamban (phosphoSer16) (Upstate, Lake Placid, NY), antiryanodine receptor (Affinity Bioreagents, Golden, CO), and anti-phospho-ryanodine receptor (phosphoSer2808) (Abcam, Cambridge, MA). The blot was also probed by a mouse monoclonal α-actin antibody as an internal control to ensure equivalent protein loading and protein integrity. Signals on the films were digitized on a 350-dots per inch scanner and analized using Image J software (NIH).
Isolation of Adult Ventricular Cardiomyocytes. Ca 2+ tolerant adult cardiomyocytes were isolated from ventricular tissue of mice by a standard enzymatic digestion procedure (9) and cultured on 24 x 50mm, No. 1 glass coverslips treated with laminin as described previously (9, 15) .
Calcium Transients. Calcium transients were recorded in freshly plated myocytes, with the use of Indo-1 or Fluo-3. The method has been described previously (6, 15, 16) Calcium transients were recorded from at least 20 cells per heart and for at least 3 hearts per treatment. Diastolic and systolic intracellular Ca 2+ levels were inferred from the basal and maximal indo-1 ratio per cycle, respectively. Diastolic decay time Statistical analysis. Results were expressed as mean+SE. The data among groups were compared using 1 way ANOVA followed by Bonferroni's post hoc test for multiple comparisons. A P value less than 0.05 was considered to be statistically significant.
Results

General
STZ-injected diabetic animals showed a significant decrease (~30%) in body weight (Table 1) . Serum glucose levels were increased in STZ-treated mice and DOX treatment did not affect glucose levels ( Table 1 ). All studied animal groups presented similar blood pressure and heart rate values (Table 1) .
We tested the hypothesis that timed inducible increased expression of SERCA2a transgene may alleviate abnormalities observed in calcium handling and cardiac contractility of diabetic mice. Therefore, SER-TG mice which were diabetic for 10 weeks were studied. A group of diabetic TG mice received DOX in their drinking water during 7 days to induce SERCA2a expression. DOX treatment did not affect the studied parameters in wild type (WT) mice (not shown). We did not observe a change in mortality in the diabetic SER-TG mice with DOX compared with SER-TG diabetic that did not receive DOX (not shown).
Induced SERCA2a expression in the diabetic heart
In order to confirm increased SERCA2a expression, protein from myocytes was subjected to SDS-PAGE. Western blot analysis revealed that STZ-induced diabetes reduced SERCA2a protein levels by 60% in SER-TG mice compared with control SER-TG (Fig. 1A,B) . Induction of SERCA2a expression increased SERCA2a levels in control SER-TG by 38% after DOX treatment compared with control SER-TG in absence of DOX. Surprisingly, SER-TG diabetic mice presented a higher SERCA2a protein levels after DOX induction compared with controls and diabetic mice (Fig. 1A,B) . Expression of inducible SERCA2a protein was observed only in the animals that received DOX as detected by the anti-flag antibody. In addition, the expression of the inducible SERCA2a was increased in the diabetic mice (Fig. 1A,B) . Basal SERCA2a expression was not different between control SER-TG and WT mice (not shown).
Influence of increased SERCA2a expression on the expression of ryanodine receptor (RyR) and phospholamban (PLB)
Hearts from SER-TG mice presented a 40% reduction in RyR protein levels after SERCA2a induction with DOX compared with control SER-TG (Fig. 1A,C) . RyR protein levels were reduced by 70% in SER-TG diabetic hearts and 66% after SERCA2a induction with DOX ( Fig. 1 A,C) . Phosphorylated RyR (p-RyR) presented the same pattern described for non-phosphorylated RyR (Fig. 1A,C) . p-RyR/RyR ratio diminished by SERCA2a expression in the normal mouse heart (Fig. 1A,C) . PLB and phospho-PLB were decreased in all groups compared with control SER-TG mouse hearts (Fig. 1A.D) .
p-PLB/PLB ratio was also decreased by ~40% in all groups compared with SER-TG hearts.
Influence of increased SERCA2a expression on contractile function and calcium transients of diabetic cardiac myocytes
Contractility in the cardiac myocyte was assessed by edge detection. Cell shortening was diminished in diabetic cardiac myocytes by 30% (Fig 2) . Rate of contraction (+dL/dt) and relaxation(-dL/dt) was also decreased in diabetic myocytes (Fig 2) .
SERCA2a induction by DOX returned these parameters to control values. We investigated if these changes in contractility were associated with corresponding alterations of calcium handling. Analysis of calcium transients showed that the rate of diastolic decay of Ca 2+ (Tdecay) was delayed in diabetic cardiac myocytes by 66% (Fig   3) . Induction of SERCA2a expression accelerated Ca 2+ decline in the diabetic myocyte above control values (fig 3) . Systolic Ca 2+ and calcium released (∆Ca 2+ ) were decreased in the diabetic myocytes and increased towards control values by SERCA2a expression (Table 1) . Diastolic calcium levels and time to peak (Tmax) did not change (Table 1) .
Effect of SERCA2a expression on global contractile function of diabetic hearts.
Diminished fractional shortening and the mean rate of circumferential shortening (VCF) measured in vivo by echocardiography in SER-TG diabetic mice was returned to normal by SERCA2a induction with DOX (Table 1) . Cardiac function in ex vivo Langendorffperfused hearts was measured using a fluid-filled intraventricular balloon. Developed left ventricular pressure was 30% lower in the diabetic heart compared with control ( Fig   4) . It was associated with slower rates of contraction (+dP/dt) and relaxation (-dP/dt).
SERCA2a overexpression was able to return these parameters to control values (Fig 4) .
Discussion
Diabetic cardiomyopathy results in significant contractile and Ca 2+ handling abnormalities in part mediated by decreased SERCA2a expression. It is currently unclear if alleviating decreased SERCA2a expression in hearts with established diabetic cardiomyopathy could still return the contractile function of the diabetic heart towards normal.
Our results show that increasing SERCA2a protein levels in mouse hearts with diabetic cardiomyopathy resulted in a dramatic improvement of contractile function and calcium handling in the myocyte. In addition, the global cardiac function of the diabetic heart was normalized.
Diabetic cardiomyopathy is characterized by reduced cardiac contractility due to direct changes in heart muscle function independent of vascular disease (1, 13 We found a dramatic decrease in SERCA2a protein levels in our diabetic model.
Induction of SERCA2a by administration of doxycycline (DOX) increased SERCA2a
levels in the diabetic heart even higher than control values (Fig 1A,B) . Different results were observed in previous studies in a model of pressure overload-induced heart failure (16). In the pressure overload model, SERCA2a levels reached only control values after SERCA2a induction in the failing heart. In this work, SERCA2a overexpression also influenced the endogenous expression of RyR and PLB. These two calcium-related proteins were down regulated in the diabetic heart (Fig. 1A,C,D) which is in agreement with other reports (10) . Surprisingly, SERCA2a induction decreased RyR and PLB in the normal mouse heart. Similar results were found in a transgenic mouse that overexpresses SERCA1a in the SR (8) . This effect of SERCA overexpression indicates a compensatory downregulation of the RyR protein expression to regulate the amount of Ca 2+ released during each contraction to counteract the increased SR Ca 2+ load caused by increased SERCA2a activity (11, 16) . Furthermore, this data strongly suggest that the improvement in cardiac contraction and relaxation is mostly due to SERCA2a overexpression. In this situation, effects related to decreased RyR and PLB expression or the phosphorylation level of these proteins would largely nullified by the effects of SERCA2a overexpression. This idea is supported by the observation that RyR, PLB, and the phosphorylated forms of these proteins appeared decreased after SERCA2a induction in control mice and decreased further in diabetic mice with no improvement after SERCA2a induction. However, contractile and calcium flux parameters were dramatically changed.
Increase in SERCA2a levels in the diabetic heart was able to return myocyte contractile parameters to the normal range. Cell shortening, rate of contraction and relaxation were higher in diabetic myocytes with increased SERCA2a expression than in control myocytes and these results are in line with the observed increased SERCA2a expression. Cytosolic calcium decline (Tdecay) in the mouse myocyte is responsible for myocyte relaxation and is mainly due to SERCA2a activity. Tdecay was markedly prolonged in the diabetic myocyte which is in agreement with previous studies (18) . 
Perspectives and Significance
Diabetes mellitus is a growing public heath concern, affecting 170 million individuals worldwide. Cardiovascular disease is the leading cause of death in diabetes. Diabetes predisposes patients to the development of a specific cardiomyopathy that increases cardiovascular risk. In this work we presented data demonstrating that expression of SERCA2a protein during a well established diabetic state is able to alleviate cardiac dysfunction of the diabetic cardiomyopathy. Further experiments can be performed to develop potential therapeutic approaches using gene therapy to induce SERCA2a expression in non-transgenic diabetic models that could be applied in humans.
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Table1. Body weight, serum levels of glucose, blood pressure, heart rate, echocardiographic parameters and cardiomyocyte calcium transient parameters of control, diabetic and diabetic plus doxycycline-treated SER-TG mice. 
